Literature DB >> 16040982

Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.

Maija Toropainen1, Leena Saarinen, Elisabeth Wedege, Karin Bolstad, Terje E Michaelsen, Audun Aase, Helena Käyhty.   

Abstract

Neisseria meningitidis, an important cause of bacterial meningitis and septicemia worldwide, is associated with high mortality and serious sequelae. Natural immunity against meningococcal disease develops with age, but the specificity and functional activity of natural antibodies associated with protection are poorly understood. We addressed this question by using a selected subset of prevaccination sera (n = 26) with convergent or discrepant serum bactericidal activity (SBA) and infant rat protective activity (IRPA) against the serogroup B meningococcal strain 44/76-SL (B:15:P1.7,16) from Icelandic teenagers. The sera were analyzed by opsonophagocytic activity (OPA) assay, immunoblotting, immunoglobulin G (IgG) quantitation against live meningococcal cells by flow cytometry, and enzyme immunosorbent assay (EIA). High levels of SBA and OPA were reflected in distinct IgG binding to major outer membrane proteins and/or lipopolysaccharide in immunoblots. However, we could not detect any specific antibody patterns on blots that could explain IRPA. Only IgM antibody to group B capsular polysaccharide (B-PS), measured by EIA, correlated positively (r = 0.76, P < 0.001) with IRPA. Normal human sera (NHS; n = 20) from healthy Finnish children of different ages (7, 14, and 24 months and 10 years) supported this finding and showed an age-related increase in IRPA that coincided with the acquisition of B-PS specific IgM antibody. The protection was independent of complement-mediated bacterial lysis, as detected by the inability of NHS to augment SBA in the presence of human or infant rat complement and the equal protective activity of NHS in rat strains with fully functional or C6-deficient complement.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16040982      PMCID: PMC1201264          DOI: 10.1128/IAI.73.8.4694-4703.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  63 in total

1.  Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine.

Authors:  A Aase; G Bjune; E A Høiby; E Rosenqvist; A K Pedersen; T E Michaelsen
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

2.  Killing of meningococci by neutrophils: effect of vaccination on patients with complement deficiency.

Authors:  M Schlesinger; R Greenberg; J Levy; H Kayhty; R Levy
Journal:  J Infect Dis       Date:  1994-08       Impact factor: 5.226

3.  Complement-mediated bactericidal activity of human antibodies to poly alpha 2-->8 N-acetylneuraminic acid, the capsular polysaccharide of Neisseria meningitidis serogroup B.

Authors:  R E Mandrell; F H Azmi; D M Granoff
Journal:  J Infect Dis       Date:  1995-11       Impact factor: 5.226

4.  Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease.

Authors:  J Holst; B Feiring; J E Fuglesang; E A Høiby; H Nøkleby; I S Aaberge; E Rosenqvist
Journal:  Vaccine       Date:  2003-01-30       Impact factor: 3.641

5.  Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation.

Authors:  A Sahu; T R Kozel; M K Pangburn
Journal:  Biochem J       Date:  1994-09-01       Impact factor: 3.857

6.  Fc gamma receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children.

Authors:  R G Bredius; B H Derkx; C A Fijen; T P de Wit; M de Haas; R S Weening; J G van de Winkel; T A Out
Journal:  J Infect Dis       Date:  1994-10       Impact factor: 5.226

7.  Evaluation of the efficacy of human antimeningococcal immunoglobulin G in infant rats experimentally infected with Neisseria meningitidis group B.

Authors:  J F Infante; O Marrero; S Sifontes; G Sierra; C Campa; E Caro; M Gutiérrez; A Malberti; V Capó; M Fariñas
Journal:  Arch Med Res       Date:  1994       Impact factor: 2.235

8.  Antibody responses to the capsular polysaccharide of Neisseria meningitidis serogroup B in patients with meningococcal disease.

Authors:  D M Granoff; S K Kelsey; H A Bijlmer; L Van Alphen; J Dankert; R E Mandrell; F H Azmi; R J Scholten
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

9.  Human immunoglobulin M paraproteins cross-reactive with Neisseria meningitidis group B polysaccharide and fetal brain.

Authors:  F H Azmi; A H Lucas; H L Spiegelberg; D M Granoff
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

10.  Development, characterization, and biological properties of meningococcal immunotype L3,7,(8),9-specific monoclonal antibodies.

Authors:  A F Verheul; A J Kuipers; A K Braat; H A Dekker; C C Peeters; H Snippe; J T Poolman
Journal:  Clin Diagn Lab Immunol       Date:  1994-11
View more
  13 in total

1.  Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats.

Authors:  Maija Toropainen; Leena Saarinen; Gestur Vidarsson; Helena Käyhty
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Authors:  Lisa A Lewis; David M Vu; Dan M Granoff; Sanjay Ram
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

3.  Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents.

Authors:  Dominique Boutriau; Jan Poolman; Ray Borrow; Jamie Findlow; Javier Diez Domingo; Joan Puig-Barbera; José María Baldó; Victoria Planelles; Angels Jubert; Julia Colomer; Angel Gil; Karin Levie; Anne-Diane Kervyn; Vincent Weynants; Francisco Dominguez; Ramon Barberá; Franklin Sotolongo
Journal:  Clin Vaccine Immunol       Date:  2006-10-25

4.  Capsular polysaccharide vaccine for Group B Neisseria meningitidis, Escherichia coli K1, and Pasteurella haemolytica A2.

Authors:  John B Robbins; Rachel Schneerson; Guilin Xie; Lars Å Hanson; Lars Åke-Hanson; Mark A Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-24       Impact factor: 11.205

5.  Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.

Authors:  Dan M Granoff; Jo Anne Welsch; Sanjay Ram
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

6.  Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England.

Authors:  Caroline Trotter; Jamie Findlow; Paul Balmer; Ann Holland; Rita Barchha; Nick Hamer; Nick Andrews; Elizabeth Miller; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

7.  Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal antibody.

Authors:  Jo Anne Welsch; Dan Granoff
Journal:  Clin Vaccine Immunol       Date:  2007-10-03

Review 8.  Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.

Authors:  Dan M Granoff
Journal:  Vaccine       Date:  2009-05-23       Impact factor: 3.641

9.  The acute-phase reactant C-reactive protein binds to phosphorylcholine-expressing Neisseria meningitidis and increases uptake by human phagocytes.

Authors:  Rosalyn Casey; Jane Newcombe; Johnjoe McFadden; Katherine B Bodman-Smith
Journal:  Infect Immun       Date:  2008-01-14       Impact factor: 3.441

10.  Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity.

Authors:  Joyce S Plested; Jo Anne Welsch; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2009-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.